Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports

Blerina Resuli; Diego Kauffmann-Guerrero; Jürgen Behr; Amanda Tufman

doi:10.1016/j.jtocrr.2024.100719

Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports

JTO Clin Res Rep. 2024 Sep 7;5(12):100719. doi: 10.1016/j.jtocrr.2024.100719. eCollection 2024 Dec.

Authors

Blerina Resuli^{1

2}, Diego Kauffmann-Guerrero^{1

2}, Jürgen Behr^{1

2}, Amanda Tufman^{1

2}

Affiliations

¹ Department of Medicine V, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
² Comprehensive Pneumology Center Munich, German Center for Lung Research, Munich, Germany.

Abstract

HER2 mutation and amplification have been identified as distinct molecular targets in lung cancer with different therapeutic and prognostic values. The coexistence of HER2 and EGFR mutations is extremely rare, and therefore, no data exist on the best treatment in these cases.

Keywords: Afatinib; Case report; EGFR mutation; HER2 mutations; Non–small cell lung cancer; Osimertinib.

Publication types

Case Reports